Verrica’s Q1 YCANTH units rise 12.1% sequentially
Verrica Pharmaceuticals saw a 12.1% sequential increase in dispensed YCANTH units in Q1 2026.
The company is targeting the initiation of COVE-3 by mid-2026.
Verrica’s growth in market demand for YCANTH set new records for dispensed applicator units during the quarter.